InvestorsHub on MSN
BioNexus Gene Lab Shares Surge on Strategic MRD Testing Partnership
BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares jumped 10% after the company announced strategic agreements with Fidelion Diagnostics to jointly commercialize VitaGuard, a next-generation liquid biopsy ...
BioNexus Gene Lab Corp. (Nasdaq: BGLC) advances precision diagnostics and AI-enabled health technologies to make next-generation testing accessible, affordable, and actionable throughout Southeast ...
Investing.com -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) stock surged 10% following the announcement of strategic agreements with Fidelion Diagnostics to commercialize VitaGuard, a liquid biopsy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback